All In Biotech

Drug Trial Radar · NCT01890837

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

Effect of Daikenchuto (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome

Last checked: Nov 19, 2026Latest source record: Jun 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 2013

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
Tsumura USAIndustry
Sponsor type
Industry
Collaborators
Cato Research
First posted
Jul 2, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto \[TU-100\] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation ratings of urgency to defecate and sensation threshold for pain) in response to rectal balloon distension by barostat in patients with IBS.

Conditions

  • Irritable Bowel Syndrome
  • Digestive System Diseases
  • Gastrointestinal Diseases
  • Intestinal Diseases
  • Abdominal Pain

Interventions

  • Daikenchuto (TU-100)Drug

    Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

  • PlaceboDrug

    Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VASTime frame: 14 days
  2. Sensation threshold for pain in response to distention of the rectumTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic, Rochester Methodist CRU

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.